Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts

PURPOSE: The National Cancer Institute has completed a first-in-human clinical pharmacodynamic (PD) trial of the targeted agent ABT-888, a poly (ADP-ribose) polymerase (PARP) inhibitor, under the auspices of the US Food and Drug Administration's Exploratory Investigational New Drug Application....

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Kinders, Robert J., Hollingshead, Melinda, Khin, Sonny, Rubinstein, Larry, Tomaszewski, Joseph E., Doroshow, James H., Parchment, Ralph E.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2008
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2766769/
https://ncbi.nlm.nih.gov/pubmed/18980982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0214
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items